WST

Healthcare

West Pharmaceutical Services

Price Chart

Market Data

Financials

XBRL · SEC EDGAR

2008–2025(18yr)

Revenue

Net Income

Free CF

Metric	FY 2008	FY 2009	FY 2010	FY 2011	FY 2012	FY 2013	FY 2014	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025Latest	YoY
Revenue	$1.1B	$1.1B	$1.1B	$1.2B	$1.3B	$1.4B	$1.4B	$1.4B	$1.5B	$1.6B	$1.7B	$1.8B	$2.1B	$2.8B	$2.9B	$2.9B	$2.9B	$3.1B	+6.3%
Gross Profit	$302.6M	$303.6M	$318.1M	$339.3M	$387.7M	$434.7M	$447.8M	$455.8M	$501.1M	$512.6M	$545.4M	$605.7M	$767.8M	$1.2B	$1.1B	$1.1B	$998.5M	$1.1B	+10.6%
Gross Margin	28.8%	28.8%	28.8%	28.5%	30.6%	31.8%	31.5%	32.6%	33.2%	32.1%	31.8%	32.9%	35.8%	41.5%	39.4%	38.3%	34.5%	35.9%	+1.4pp
Operating Income	$124.1M	$97.5M	$90.7M	$109.6M	$135.1M	$162.4M	$182.0M	$128.6M	$196.8M	$228.9M	$240.3M	$296.6M	$406.9M	$752.3M	$734.0M	$676.0M	$569.9M	$584.9M	+2.6%
Operating Margin	11.8%	9.2%	8.2%	9.2%	10.7%	11.9%	12.8%	9.2%	13.0%	14.3%	14.0%	16.1%	19.0%	26.6%	25.4%	22.9%	19.7%	19.0%	-0.7pp
Net Income	$86.0M	$72.6M	$65.3M	$75.5M	$80.7M	$112.3M	$127.1M	$95.6M	$143.6M	$150.7M	$206.9M	$241.7M	$346.2M	$661.8M	$585.9M	$593.4M	$492.7M	$493.7M	+0.2%
Net Margin	8.2%	6.9%	5.9%	6.3%	6.4%	8.2%	8.9%	6.8%	9.5%	9.4%	12.0%	13.1%	16.1%	23.4%	20.3%	20.1%	17.0%	16.1%	-1.0pp
Free Cash Flow	-$3.6M	$32.8M	$67.2M	$35.3M	$56.1M	$68.6M	$71.0M	$80.8M	$49.2M	$132.5M	$183.9M	$240.8M	$298.1M	$330.6M	$439.4M	$414.5M	$276.4M	$468.9M	+69.6%
FCF Margin	-0.3%	3.1%	6.1%	3.0%	4.4%	5.0%	5.0%	5.8%	3.3%	8.3%	10.7%	13.1%	13.9%	11.7%	15.2%	14.1%	9.6%	15.3%	+5.7pp
EPS (Diluted)	$2.50	$2.12	$1.89	$2.16	$2.30	$1.57	$1.75	$1.30	$1.91	$1.99	$2.74	$3.21	$4.57	$8.67	$7.73	$7.88	$6.69	$6.79	+1.5%

Total Debt$202.8M

Cash & Equiv.$791.3M

Net Cash$588.5M

3 min read

1. THE BIG PICTURE

West Pharmaceutical Services is no longer just a manufacturer of stoppers and vials; it has successfully embedded itself into the drug development lifecycle through integrated "high-value" solutions. While total revenue growth is modest, West Pharmaceutical Services is extracting significantly more profit from its existing footprint by shifting customers toward complex delivery devices and analytical services that carry higher switching costs.

2. WHERE THE RISKS HIT HARDEST

The "integrated service model" that West uses to create a competitive moat is directly threatened by the risk of "product obsolescence" (10-K Item 1A). Because West’s advantage is rooted in being a "global supplier of integrated drug containment," its fortunes are tied to the delivery method itself; if pharmaceutical customers successfully shift toward oral GLP-1s or reconfigure products to require less frequent dosing, the demand for West’s specialized elastomers and delivery devices would contract regardless of its technical expertise (10-K Item 1). Furthermore, West Pharmaceutical Services’s "global manufacturing footprint" is a double-edged sword. While it ensures supply continuity, it leaves 56.7% of sales exposed to international trade protectionism and currency volatility, which can obscure the underlying performance of its core segments (10-K Item 1A).

3. WHAT THE NUMBERS SAY TOGETHER

A comparison across the peer group reveals a distinct operating profile: West maintains the lowest gross margin among its peers at 35.3%, yet it achieves the second-highest operating margin at 19.5% (XBRL). This indicates that while the physical production of plastic and aluminum components is capital-intensive, West is exceptionally efficient at managing its overhead and specialized services compared to larger peers like BDX. The 7.5% revenue growth in the most recent quarter represents a slight acceleration over the trailing twelve-month average of 6.3%, fueled by a 20.3% surge in High-Value Product (HVP) Components (8-K). However, sentiment is somewhat tempered by a short interest of 4.1% of the float, suggesting some market skepticism regarding the sustainability of this growth (Yahoo Finance).

4. IS IT WORTH IT AT THIS PRICE?

At 26.3x Forward P/EP/EPrice-to-Earnings ratio — share price divided by annual earnings per share; how much investors pay per dollar of profit. Higher P/E = higher growth expectations, West trades at a 69% premium to the peer median of 15.6x (XBRL). The market is pricing in approximately 7.2% long-term growth (CAPM analysis). While the HVP business is currently delivering double-digit growth, West Pharmaceutical Services’s own 2026 guidance forecasts more conservative organic net sales growth of 5% to 7% (8-K). This creates a valuation gap; if long-term growth were to align with a 5% "base case," the justified multiple would fall to 16.7x—a significant distance from current trading levels (CAPM analysis). Investors are paying a premium for a clean balance sheet featuring $425.8 million in net cash, but they are receiving the lowest buyback yield (1.1%) and the second-lowest dividend yield (0.3%) in the peer group (XBRL).

5. WHAT WOULD CHANGE THIS VIEW?

Cautious if HVP component growth falls below 15%, as this specific sub-segment is the primary engine for the double-digit earnings growth management has promised.
Constructive if 2026 organic sales growth exceeds the high end of the 7% guidance range, providing the fundamental support needed for the current valuation premium.
Cautious if there is a measurable decline in "HVP Delivery Devices," which already saw a 16.9% decline in the most recent quarter (8-K).

6. BOTTOM LINE

Structural Advantage: High switching costs created by the integration of primary packaging components with proprietary analytical lab services and regulatory expertise. Bottom Line: West is a high-quality specialist trading at a significant price premium that leaves no room for a slowdown in the injectable drug market.

Source: Synthesis · LLM Analysis

4 min read

1. Top 5 Material Risks

International Exposure: With 56.7% of 2025 consolidated net sales generated outside the U.S., West Pharmaceutical Services is highly sensitive to foreign currency fluctuations, political instability, and trade protectionism, which can impact the comparability of period-to-period results.
Product Obsolescence and Delivery Shifts: Sales and profitability depend on the continued use of injectable drug delivery systems; a shift toward alternative delivery methods (such as oral GLP-1s) or product reconfigurations requiring less frequent dosing would directly reduce demand.
Pricing Pressure and Competition: West Pharmaceutical Services faces aggressive cost-control programs from pharmaceutical customers and competition from firms that may have greater financial resources, forcing West Pharmaceutical Services to defend its profit margins against pricing pressure.
Manufacturing Concentration: The production of certain product lines is concentrated in one or few facilities, meaning disruptions from natural disasters, power outages, or labor actions could halt the ability to make and sell products.
Raw Material and Energy Costs: West Pharmaceutical Services relies on three basic raw materials—elastomers, aluminum, and plastic—and significant energy consumption; volatility in these costs, combined with a time delay in passing price increases to customers, threatens profitability.

2. Company-Specific Risks

Daikyo License Dependency: Key proprietary technologies, including Crystal Zenith, FluroTec®, and B2-coating, are licensed from Daikyo under agreements expiring in 2027; failure to renew these or early termination would disrupt access to critical product lines.
Strategic Transaction Integration: Acquisitions and divestitures, such as the recent sale of the SmartDose® 3.5mL On-Body Delivery System to AbbVie, carry risks of failing to realize expected synergies, diverting management attention, or retaining lingering warranty and indemnification liabilities.
Filling Capacity Constraints: The commercialization of new products, particularly those using Crystal Zenith vials, syringes, and cartridges, is dependent on the timely availability of filling capacity, which is outside West Pharmaceutical Services's direct control.
Customer Concentration: A substantial portion of revenue is derived from a limited number of customers, making West Pharmaceutical Services vulnerable to the loss of, or reduced orders from, any single key account.

3. Regulatory/Legal Risks

Regulatory Approval Timelines: Products are subject to extensive FDA and international approval processes, such as the 510(k) process (typically six to nine months) or longer New Drug Application and Biologics License Application reviews, which create uncertainty in commercialization timing.
Data Privacy Compliance: West Pharmaceutical Services must navigate complex, conflicting global data privacy laws (e.g., EU GDPR, UK GDPR, CCPA/CPRA), where failure to comply could lead to significant fines, regulatory investigations, or injunctions against data processing.
Environmental and PFAS Regulations: Emerging restrictions on per and polyfluoroalkyl substances (PFAS) in packaging, particularly in the EU and certain U.S. states, could force costly product modifications or result in non-compliance penalties.
Anti-Corruption Enforcement: As a global entity, West Pharmaceutical Services is subject to the U.S. Foreign Corrupt Practices Act (FCPA) and the U.K. Bribery Act; any violation by employees or third-party intermediaries could result in significant fines, loss of export privileges, and reputational damage.

4. Financial Impact Map

International Operations → Net Sales → 56.7% of consolidated net sales in 2025 generated outside the U.S. Raw Material and Energy Price Volatility → Profitability/Gross Margin → Time delay between cost increases and the ability to raise customer prices. Manufacturing Disruptions → Revenue/Operating Income → Concentration of product lines in limited facilities creates risk of total production halts. Customer Concentration → Net Sales → Loss of key customers would have a material adverse impact on financial condition and operating results. Strategic Transactions → Goodwill and Intangible Assets → Potential for future charges to recognize impairment in carrying values if expected benefits are not realized.

Source: 10-K Item 1A · LLM Analysis

Recent Filings

Form	Filed	Period
10-K	Feb 2026	Dec 2025
8-K	Feb 2026	—
10-Q	Oct 2025	Sep 2025
14A	Mar 2025	—